Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | DTRM-12 with everolimus and pomalidomide in R/R CLL and B-cell lymphomas

Anthony Mato • 7 Dec 2019
ASH 2019
B-Cell Lymphoma Chronic Lymphocytic Leukemia Diffuse Large B-Cell Lymphoma Leukemia Lymphoma Non-Hodgkin Lymphoma DTRM-12 Everolimus Pomalidomide

Anthony Mato, MD, MSCE, Memorial Sloan Kettering Cancer Center, New York, NY, discusses a phase Ia/Ib study (NCT02900716) exploring the synthetic lethality of the orally administered novel BTK inhibitor, dtrmwxhs-12 (DTRM-12), in combination with everolimus and pomalidomide (DTRM-555) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL) or other B-cell lymphomas. Encouraging clinical activity was observed in several high-risk, multi-refractory CLL and lymphoma patients. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Anthony Mato

1:42
The importance of genomic testing in CLL prognosis
Anthony Mato • 18 Mar 2022
1:34
Time-limited vs continuous therapy in CLL treatment
Anthony Mato • 18 Mar 2022
2:58
Updates on non-covalent BTK inhibitors and their place in CLL treatment
Anthony Mato • 18 Mar 2022
1:37
Pirtobrutinib resistance in CLL: early findings
Anthony Mato • 18 Mar 2022

Related Videos

1:17
An ongoing Phase I/II study of sonrotoclax + zanubrutinib in patients with treatment-naive CLL/SLL
Piers Patten • 28 Apr 2024
1:51
Should MRD eradication be the goal when treating every patient with CLL?
Dima El-Sharkawi • 28 Apr 2024
1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
The content of VJHemOnc is intended for healthcare professionals